<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03627299</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00174409</org_study_id>
    <nct_id>NCT03627299</nct_id>
  </id_info>
  <brief_title>Renal Transplants in Hepatitis C Negative Recipients With Nucleic Acid Positive Donors</brief_title>
  <official_title>An Open-label Pilot Study to Determine the Safety and Efficacy of Fixed-dose Glecaprevir and Pibrentasvir Treatment in Hepatitis C Uninfected Recipients of Renal Transplants From Hepatitis C Infected Deceased Donors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, individuals without hepatitis C infection who are on the kidney transplant&#xD;
      waitlist will receive a kidney from a deceased donor with hepatitis C infection and will be&#xD;
      treated for hepatitis C at the same time. Treatment will include glecaprevir 300 mg /&#xD;
      pibrentasvir 120 mg (G-P) administered on-call to the operating room for the renal transplant&#xD;
      procedure and continued for 4 weeks post-renal transplant.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, individuals without hepatitis C infection who are on the kidney transplant&#xD;
      waitlist will receive a kidney from a deceased donor with hepatitis C infection and will be&#xD;
      treated for hepatitis C at the same time. Treatment will include glecaprevir 300 mg /&#xD;
      pibrentasvir 120 mg (G-P) administered on-call to the operating room for the renal transplant&#xD;
      procedure and continued for 4 weeks post-renal transplant. The participant will continue to&#xD;
      be tested for Hepatitis C for 12 weeks post-treatment.&#xD;
&#xD;
      The primary hypothesis is that prophylactic treatment with glecaprevir/pibrentasvir before&#xD;
      and after transplant will prevent the establishment of HCV infection in the recipients of&#xD;
      kidneys from HCV-infected deceased donors. Based on the success of preliminary studies, the&#xD;
      objective of the study is to evaluate the safety and efficacy of 4 weeks of G-P as&#xD;
      prophylaxis for HCV D+/R- kidney transplant.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 25, 2018</start_date>
  <completion_date type="Actual">September 20, 2021</completion_date>
  <primary_completion_date type="Actual">December 19, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Viral Response at Week 12</measure>
    <time_frame>12 weeks after completing therapy</time_frame>
    <description>This is the number of participants with undetectable hepatitis C RNA in the blood at 12 weeks after stopping treatment. Proportion of kidney transplant recipients with HCV RNA &lt; Lower Limit Of Quantification (LLOQ) at week 12</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Grade 3 or Higher Treatment-related Adverse Events Related to the Use of G-P</measure>
    <time_frame>4 weeks after transplant</time_frame>
    <description>Proportion of participants with grade 3 or higher treatment-related adverse events (AE) as assessed by US Department of Health and Human Services Common Terminology of AEs version 4. An AE is an unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medical treatment or procedure that may or may not be considered related to the medical treatment or procedure. Grade refers to the severity of the AE. The CTCAE displays Grades 1 through 5. Grade 3 Severe or medically significant but not life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; Grade 4 Life-threatening consequences; urgent intervention indicated. Grade 5 Death related to AE. The investigator will determine if the AE is related to the treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Viral Response at 1 Week</measure>
    <time_frame>1 week after completing therapy</time_frame>
    <description>This is the number of participants with undetectable hepatitis C RNA in the blood at 1 week after stopping treatment. Proportion of kidney transplant recipients with HCV RNA &lt; Lower Limit Of Quantification (LLOQ) at week 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral Response at 2 Weeks</measure>
    <time_frame>2 weeks after completing therapy</time_frame>
    <description>This is the number of participants with undetectable hepatitis C RNA in the blood at 2 weeks after stopping treatment. Proportion of kidney transplant recipients with HCV RNA &lt; Lower Limit Of Quantification (LLOQ) at week 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral Response at 4 Weeks</measure>
    <time_frame>4 weeks after completing therapy</time_frame>
    <description>This is the number of participants with undetectable hepatitis C RNA in the blood at 4 weeks after stopping treatment. Proportion of kidney transplant recipients with HCV RNA &lt; Lower Limit Of Quantification (LLOQ) at week 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral Response at 8 Weeks</measure>
    <time_frame>8 weeks after completing therapy</time_frame>
    <description>This is the number of participants with undetectable hepatitis C RNA in the blood at 8 weeks after stopping treatment. Proportion of kidney transplant recipients with HCV RNA &lt; Lower Limit Of Quantification (LLOQ) at week 8</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody Development</measure>
    <time_frame>week 12 after discontinuation of therapy</time_frame>
    <description>Number of kidney transplant recipients that become reactive for HCV antibody</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T-cell Response at Baseline</measure>
    <time_frame>Baseline prior to induction therapy</time_frame>
    <description>Measurement of t-cell response to HCV peptides, a marker of acute hepatitis C infection. This categorizes participants into no T-cell response, T-cell response to 1 peptide, T-cell response to 2 peptides and T-cell response to 3 peptides.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T-cell Response at 12 Weeks</measure>
    <time_frame>Week12 after discontinuation of therapy</time_frame>
    <description>Measurement of t-cell response to HCV peptides, a marker of acute hepatitis C infection. This categorizes participants into no T-cell response, T-cell response to 1 peptide, T-cell response to 2 peptides and T-cell response to 3 peptides.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kidney Function at 6 Months</measure>
    <time_frame>6 months following transplant</time_frame>
    <description>Serum creatinine mg/dL at 6 months following transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kidney Function at 12 Months</measure>
    <time_frame>12 months following transplant</time_frame>
    <description>Serum creatinine mg/dL at 12 months following transplantation</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>End Stage Renal Disease</condition>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Deceased donor HCV RNA PCR+</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who receive a kidney from HCV RNA PCR + deceased donor will receive 300 mg glecaprevir/pibrentasivir 120 mg once daily by mouth for 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>300mg glecaprevir/pibrentasivir 120mg</intervention_name>
    <description>300mg glecaprevir/pibrentasivir 120mg 4 weeks post-transplant</description>
    <arm_group_label>Deceased donor HCV RNA PCR+</arm_group_label>
    <other_name>Mavyret</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Recipient Inclusion Criteria&#xD;
&#xD;
          -  Participants ≥ 40 years old&#xD;
&#xD;
          -  On the deceased donor kidney waitlist at Johns Hopkins Hospital&#xD;
&#xD;
          -  Awaiting a first or second kidney transplant&#xD;
&#xD;
          -  No available living kidney donors&#xD;
&#xD;
          -  On hemodialysis or peritoneal dialysis or stage 5 chronic kidney disease defined as a&#xD;
             glomerular filtration rate &lt;15 ml/min for ≥ past 90 days&#xD;
&#xD;
          -  HCV-uninfected (by both antibody and RNA PCR) and without any behavioral risk factors&#xD;
             for contracting HCV other than being on hemodialysis&#xD;
&#xD;
          -  Calculated panel reactive anti-human leukocyte antigen antibody (cPRA) below 80%&#xD;
&#xD;
        Recipient Exclusion Criteria&#xD;
&#xD;
          -  Plan to receive a multi-organ transplant&#xD;
&#xD;
          -  Plan to receive a dual kidney transplant (including en bloc)&#xD;
&#xD;
          -  Prior solid organ transplant&#xD;
&#xD;
          -  Participating in another study that involves an intervention or investigational&#xD;
             product&#xD;
&#xD;
          -  Plan to receive a blood type incompatible kidney&#xD;
&#xD;
          -  History of human immunodeficiency (HIV), hepatitis C (HCV), or active hepatitis B&#xD;
             (HBV) infection, defined as being on active antiviral treatment for HBV, detectable&#xD;
             hepatitis B surface Ag or detectable hepatitis B DNA&#xD;
&#xD;
          -  Unable to safely substitute or discontinue a medication that is contraindicated with&#xD;
             the study medication&#xD;
&#xD;
          -  Psychiatric or physical illness that in the opinion of the investigator would make it&#xD;
             unsafe to proceed with transplantation or interfere with the ability of the subject to&#xD;
             participate in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christine Durand, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 8, 2018</study_first_submitted>
  <study_first_submitted_qc>August 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2018</study_first_posted>
  <results_first_submitted>August 10, 2020</results_first_submitted>
  <results_first_submitted_qc>August 10, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 24, 2020</results_first_posted>
  <last_update_submitted>September 21, 2021</last_update_submitted>
  <last_update_submitted_qc>September 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Peer reviewed publications</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 16, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/99/NCT03627299/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Of 11 participants who signed consent, 10 received organ offers from HCV+ deceased donors. The remaining participant did not receive an offer before enrollment in the study closed.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Deceased Donor HCV RNA PCR+</title>
          <description>Participants who receive a kidney from HCV RNA PCR + deceased donor will receive 300 mg glecaprevir/pibrentasivir 120 mg once daily by mouth for 4 weeks&#xD;
300mg glecaprevir/pibrentasivir 120mg: 300mg glecaprevir/pibrentasivir 120mg 4 weeks post-transplant</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Deceased Donor HCV RNA PCR+</title>
          <description>Participants who receive a kidney from HCV RNA PCR + deceased donor will receive 300 mg glecaprevir/pibrentasivir 120 mg once daily by mouth for 4 weeks&#xD;
300mg glecaprevir/pibrentasivir 120mg: 300mg glecaprevir/pibrentasivir 120mg 4 weeks post-transplant</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67" lower_limit="40" upper_limit="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Primary Cause of Renal Failure</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hypertension</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Polycystic Kidney Disease</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Glomerulonephritis</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Nephrolithiasis</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Reflux Nephropathy</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Blood Type</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>O</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>A or AB</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>B</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Viral Response at Week 12</title>
        <description>This is the number of participants with undetectable hepatitis C RNA in the blood at 12 weeks after stopping treatment. Proportion of kidney transplant recipients with HCV RNA &lt; Lower Limit Of Quantification (LLOQ) at week 12</description>
        <time_frame>12 weeks after completing therapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Deceased Donor HCV RNA PCR+</title>
            <description>Participants who receive a kidney from HCV RNA PCR + deceased donor will receive 300 mg glecaprevir/pibrentasivir 120 mg once daily by mouth for 4 weeks&#xD;
300mg glecaprevir/pibrentasivir 120mg: 300mg glecaprevir/pibrentasivir 120mg 4 weeks post-transplant</description>
          </group>
        </group_list>
        <measure>
          <title>Viral Response at Week 12</title>
          <description>This is the number of participants with undetectable hepatitis C RNA in the blood at 12 weeks after stopping treatment. Proportion of kidney transplant recipients with HCV RNA &lt; Lower Limit Of Quantification (LLOQ) at week 12</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Grade 3 or Higher Treatment-related Adverse Events Related to the Use of G-P</title>
        <description>Proportion of participants with grade 3 or higher treatment-related adverse events (AE) as assessed by US Department of Health and Human Services Common Terminology of AEs version 4. An AE is an unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medical treatment or procedure that may or may not be considered related to the medical treatment or procedure. Grade refers to the severity of the AE. The CTCAE displays Grades 1 through 5. Grade 3 Severe or medically significant but not life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; Grade 4 Life-threatening consequences; urgent intervention indicated. Grade 5 Death related to AE. The investigator will determine if the AE is related to the treatment.</description>
        <time_frame>4 weeks after transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Deceased Donor HCV RNA PCR+</title>
            <description>Participants who receive a kidney from HCV RNA PCR + deceased donor will receive 300 mg glecaprevir/pibrentasivir 120 mg once daily by mouth for 4 weeks&#xD;
300mg glecaprevir/pibrentasivir 120mg: 300mg glecaprevir/pibrentasivir 120mg 4 weeks post-transplant</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Grade 3 or Higher Treatment-related Adverse Events Related to the Use of G-P</title>
          <description>Proportion of participants with grade 3 or higher treatment-related adverse events (AE) as assessed by US Department of Health and Human Services Common Terminology of AEs version 4. An AE is an unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medical treatment or procedure that may or may not be considered related to the medical treatment or procedure. Grade refers to the severity of the AE. The CTCAE displays Grades 1 through 5. Grade 3 Severe or medically significant but not life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; Grade 4 Life-threatening consequences; urgent intervention indicated. Grade 5 Death related to AE. The investigator will determine if the AE is related to the treatment.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Viral Response at 1 Week</title>
        <description>This is the number of participants with undetectable hepatitis C RNA in the blood at 1 week after stopping treatment. Proportion of kidney transplant recipients with HCV RNA &lt; Lower Limit Of Quantification (LLOQ) at week 1</description>
        <time_frame>1 week after completing therapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Deceased Donor HCV RNA PCR+</title>
            <description>Participants who receive a kidney from HCV RNA PCR + deceased donor will receive 300 mg glecaprevir/pibrentasivir 120 mg once daily by mouth for 4 weeks&#xD;
300mg glecaprevir/pibrentasivir 120mg: 300mg glecaprevir/pibrentasivir 120mg 4 weeks post-transplant</description>
          </group>
        </group_list>
        <measure>
          <title>Viral Response at 1 Week</title>
          <description>This is the number of participants with undetectable hepatitis C RNA in the blood at 1 week after stopping treatment. Proportion of kidney transplant recipients with HCV RNA &lt; Lower Limit Of Quantification (LLOQ) at week 1</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Viral Response at 2 Weeks</title>
        <description>This is the number of participants with undetectable hepatitis C RNA in the blood at 2 weeks after stopping treatment. Proportion of kidney transplant recipients with HCV RNA &lt; Lower Limit Of Quantification (LLOQ) at week 2</description>
        <time_frame>2 weeks after completing therapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Deceased Donor HCV RNA PCR+</title>
            <description>Participants who receive a kidney from HCV RNA PCR + deceased donor will receive 300 mg glecaprevir/pibrentasivir 120 mg once daily by mouth for 4 weeks&#xD;
300mg glecaprevir/pibrentasivir 120mg: 300mg glecaprevir/pibrentasivir 120mg 4 weeks post-transplant</description>
          </group>
        </group_list>
        <measure>
          <title>Viral Response at 2 Weeks</title>
          <description>This is the number of participants with undetectable hepatitis C RNA in the blood at 2 weeks after stopping treatment. Proportion of kidney transplant recipients with HCV RNA &lt; Lower Limit Of Quantification (LLOQ) at week 2</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Viral Response at 4 Weeks</title>
        <description>This is the number of participants with undetectable hepatitis C RNA in the blood at 4 weeks after stopping treatment. Proportion of kidney transplant recipients with HCV RNA &lt; Lower Limit Of Quantification (LLOQ) at week 4</description>
        <time_frame>4 weeks after completing therapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Deceased Donor HCV RNA PCR+</title>
            <description>Participants who receive a kidney from HCV RNA PCR + deceased donor will receive 300 mg glecaprevir/pibrentasivir 120 mg once daily by mouth for 4 weeks&#xD;
300mg glecaprevir/pibrentasivir 120mg: 300mg glecaprevir/pibrentasivir 120mg 4 weeks post-transplant</description>
          </group>
        </group_list>
        <measure>
          <title>Viral Response at 4 Weeks</title>
          <description>This is the number of participants with undetectable hepatitis C RNA in the blood at 4 weeks after stopping treatment. Proportion of kidney transplant recipients with HCV RNA &lt; Lower Limit Of Quantification (LLOQ) at week 4</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Viral Response at 8 Weeks</title>
        <description>This is the number of participants with undetectable hepatitis C RNA in the blood at 8 weeks after stopping treatment. Proportion of kidney transplant recipients with HCV RNA &lt; Lower Limit Of Quantification (LLOQ) at week 8</description>
        <time_frame>8 weeks after completing therapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Deceased Donor HCV RNA PCR+</title>
            <description>Participants who receive a kidney from HCV RNA PCR + deceased donor will receive 300 mg glecaprevir/pibrentasivir 120 mg once daily by mouth for 4 weeks&#xD;
300mg glecaprevir/pibrentasivir 120mg: 300mg glecaprevir/pibrentasivir 120mg 4 weeks post-transplant</description>
          </group>
        </group_list>
        <measure>
          <title>Viral Response at 8 Weeks</title>
          <description>This is the number of participants with undetectable hepatitis C RNA in the blood at 8 weeks after stopping treatment. Proportion of kidney transplant recipients with HCV RNA &lt; Lower Limit Of Quantification (LLOQ) at week 8</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Antibody Development</title>
        <description>Number of kidney transplant recipients that become reactive for HCV antibody</description>
        <time_frame>week 12 after discontinuation of therapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Deceased Donor HCV RNA PCR+</title>
            <description>Participants who receive a kidney from HCV RNA PCR + deceased donor will receive 300 mg glecaprevir/pibrentasivir 120 mg once daily by mouth for 4 weeks&#xD;
300mg glecaprevir/pibrentasivir 120mg: 300mg glecaprevir/pibrentasivir 120mg 4 weeks post-transplant</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Development</title>
          <description>Number of kidney transplant recipients that become reactive for HCV antibody</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>T-cell Response at Baseline</title>
        <description>Measurement of t-cell response to HCV peptides, a marker of acute hepatitis C infection. This categorizes participants into no T-cell response, T-cell response to 1 peptide, T-cell response to 2 peptides and T-cell response to 3 peptides.</description>
        <time_frame>Baseline prior to induction therapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Deceased Donor HCV RNA PCR+</title>
            <description>Participants who receive a kidney from HCV RNA PCR + deceased donor will receive 300 mg glecaprevir/pibrentasivir 120 mg once daily by mouth for 4 weeks&#xD;
300mg glecaprevir/pibrentasivir 120mg: 300mg glecaprevir/pibrentasivir 120mg 4 weeks post-transplant</description>
          </group>
        </group_list>
        <measure>
          <title>T-cell Response at Baseline</title>
          <description>Measurement of t-cell response to HCV peptides, a marker of acute hepatitis C infection. This categorizes participants into no T-cell response, T-cell response to 1 peptide, T-cell response to 2 peptides and T-cell response to 3 peptides.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>No T-cell response at baseline</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>T-cell response to 1 peptide at baseline</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>T-cell response to 2 peptides at baseline</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>T-cell response to 3 peptides at baseline</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>T-cell Response at 12 Weeks</title>
        <description>Measurement of t-cell response to HCV peptides, a marker of acute hepatitis C infection. This categorizes participants into no T-cell response, T-cell response to 1 peptide, T-cell response to 2 peptides and T-cell response to 3 peptides.</description>
        <time_frame>Week12 after discontinuation of therapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Deceased Donor HCV RNA PCR+</title>
            <description>Participants who receive a kidney from HCV RNA PCR + deceased donor will receive 300 mg glecaprevir/pibrentasivir 120 mg once daily by mouth for 4 weeks&#xD;
300mg glecaprevir/pibrentasivir 120mg: 300mg glecaprevir/pibrentasivir 120mg 4 weeks post-transplant</description>
          </group>
        </group_list>
        <measure>
          <title>T-cell Response at 12 Weeks</title>
          <description>Measurement of t-cell response to HCV peptides, a marker of acute hepatitis C infection. This categorizes participants into no T-cell response, T-cell response to 1 peptide, T-cell response to 2 peptides and T-cell response to 3 peptides.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>No T-cell response at 12 weeks</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>T-cell response to 1 peptide at 12 weeks</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>T-cell response to 2 peptides at 12 weeks</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>T-cell response to 3 peptides at 12 weeks</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Kidney Function at 6 Months</title>
        <description>Serum creatinine mg/dL at 6 months following transplantation</description>
        <time_frame>6 months following transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Deceased Donor HCV RNA PCR+</title>
            <description>Participants who receive a kidney from HCV RNA PCR + deceased donor will receive 300 mg glecaprevir/pibrentasivir 120 mg once daily by mouth for 4 weeks&#xD;
300mg glecaprevir/pibrentasivir 120mg: 300mg glecaprevir/pibrentasivir 120mg 4 weeks post-transplant</description>
          </group>
        </group_list>
        <measure>
          <title>Kidney Function at 6 Months</title>
          <description>Serum creatinine mg/dL at 6 months following transplantation</description>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.32" lower_limit="0.8" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Kidney Function at 12 Months</title>
        <description>Serum creatinine mg/dL at 12 months following transplantation</description>
        <time_frame>12 months following transplant</time_frame>
        <population>One participant did not have serum creatinine checked at 12 months post-transplantation.</population>
        <group_list>
          <group group_id="O1">
            <title>Deceased Donor HCV RNA PCR+</title>
            <description>Participants who receive a kidney from HCV RNA PCR + deceased donor will receive 300 mg glecaprevir/pibrentasivir 120 mg once daily by mouth for 4 weeks&#xD;
300mg glecaprevir/pibrentasivir 120mg: 300mg glecaprevir/pibrentasivir 120mg 4 weeks post-transplant</description>
          </group>
        </group_list>
        <measure>
          <title>Kidney Function at 12 Months</title>
          <description>Serum creatinine mg/dL at 12 months following transplantation</description>
          <population>One participant did not have serum creatinine checked at 12 months post-transplantation.</population>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.33" lower_limit="0.79" upper_limit="4.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected for 12 months from initiation of treatment</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Deceased Donor HCV RNA PCR+</title>
          <description>Participants who receive a kidney from HCV RNA PCR + deceased donor will receive 300 mg glecaprevir/pibrentasivir 120 mg once daily by mouth for 4 weeks&#xD;
300mg glecaprevir/pibrentasivir 120mg: 300mg glecaprevir/pibrentasivir 120mg 4 weeks post-transplant</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Vein Thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Acute Kidney Injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Perinephric Fluid Collection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Christine Durand, MD</name_or_title>
      <organization>Johns Hopkins University</organization>
      <phone>410-955-5684</phone>
      <email>ChristineDurand@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

